Gavi, the Vaccine Alliance. (2021, November 25). Around the world, there are now 132 COVID-19 vaccine candidates undergoing clinical trials and 194 candidates in pre-clinical development. Read our latest #COVID19 vaccine race update: Https://t.co/ETtHP6XmYI [Tweet]. @gavi. https://twitter.com/gavi/status/1463953132120010753

Wallis, C. (n.d.). COVID Has Pushed Medical Research into Remote Trials, Benefiting Patients and Scientists. Scientific American. https://doi.org/10.1038/scientificamerican0521-24

Kai Kupferschmidt. (2021, March 16). “I’m not here to give you the outcome of any scientific review”, says EMA director Emer Cooke at start of press conference on AstraZeneca vaccine safety. ‘I’m here to explain the steps in the process, what we’re doing, and when you can expect us to come to a conclusion.’ [Tweet]. @kakape. https://twitter.com/kakape/status/1371811123197001729

CNN, A. S. (n.d.). Pfizer begins Phase 2 and 3 trial of Covid-19 antiviral Paxlovid in children ages 6 to 17. CNN. Retrieved 22 March 2022, from https://www.cnn.com/2022/03/09/health/pfizer-paxlovid-pediatric-trial/index.html

Mancini, D. P., & Smyth, J. (2022, February 16). Merck struggles to win European approval for Covid-19 antiviral pill. Financial Times. https://www.ft.com/content/2cf0b6cc-b07b-4ff9-a833-42eb1798a576

Hause, A. M. (2021). COVID-19 Vaccine Safety in Children Aged 5–11 Years—United States, November 3–December 19, 2021. MMWR. Morbidity and Mortality Weekly Report, 70. https://doi.org/10.15585/mmwr.mm705152a1

Prof. Akiko Iwasaki. (2022, January 27). Vaccines that reduce infection & disease are needed to combat the pandemic. Here, @tianyangmao @BenIsraelow et al. Describe our new mucosal booster strategy, Prime and Spike, to induce such immunity via nasal delivery of unadjuvanted spike vaccine 🧵 (1/) https://biorxiv.org/content/10.1101/2022.01.24.477597v1 https://t.co/bcB5MFph9F [Tweet]. @VirusesImmunity. https://twitter.com/VirusesImmunity/status/1486510697332842498

Devlin, H., & correspondent, H. D. S. (2022, February 3). Novavax Covid vaccine approved for use in over-18s in UK. The Guardian. https://www.theguardian.com/society/2022/feb/03/novavax-covid-vaccine-approved-for-use-in-over-18s-in-uk

Convalescent plasma not efficacious in hospitalized COVID-19 patients. (n.d.). Retrieved December 17, 2021, from https://medicalxpress.com/news/2021-12-convalescent-plasma-efficacious-hospitalized-covid-.html

Simon, M. A., Luginbuhl, R. D., & Parker, R. (2021). Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 Diagnosis and Up to 12 Weeks After (p. 2021.11.17.21263608). https://doi.org/10.1101/2021.11.17.21263608

Heitmann, J. S., Bilich, T., Tandler, C., Nelde, A., Maringer, Y., Marconato, M., Reusch, J., Jäger, S., Denk, M., Richter, M., Anton, L., Weber, L. M., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Hörber, S., Peter, A., Meisner, C., … Walz, J. S. (2021). A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04232-5

Devlin, H., & Kollewe, J. (2021, November 26). BioNTech says it could tweak Covid vaccine in 100 days if needed. The Guardian. https://www.theguardian.com/society/2021/nov/26/biontech-says-it-could-tweak-covid-vaccine-in-100-days-if-needed

Jabagi, M. J., Botton, J., Bertrand, M., Weill, A., Farrington, P., Zureik, M., & Dray-Spira, R. (2021). Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. JAMA. https://doi.org/10.1001/jama.2021.21699

COVID-19 vaccine surveillance report—Week 47. (n.d.). 46.

Yang, M. (2021, November 23). Seven doctors contract Covid after attending Florida anti-vaccine summit. The Guardian. https://www.theguardian.com/us-news/2021/nov/23/florida-doctors-covid-coronavirus-bruce-boros

Reardon, S. (2021). Cuba’s bet on home-grown COVID vaccines is paying off. Nature. https://doi.org/10.1038/d41586-021-03470-x

Couzin-Frankel, J. (2021). Antiviral pills could change pandemic’s course. Science, 374(6569), 799–800. https://doi.org/10.1126/science.acx9605

Walter, E. B., Talaat, K. R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G. C., Barnett, E. D., Muñoz, F. M., Maldonado, Y., Pahud, B. A., Domachowske, J. B., Simões, E. A. F., Sarwar, U. N., Kitchin, N., Cunliffe, L., Rojo, P., Kuchar, E., Rämet, M., Munjal, I., … Gruber, W. C. (2021). Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine, NEJMoa2116298. https://doi.org/10.1056/NEJMoa2116298

Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 – Valneva. (n.d.). Retrieved October 26, 2021, from https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/

Waltz, E. (2021). COVID vaccine makers brace for a variant worse than Delta. Nature, d41586-021-02854–3. https://doi.org/10.1038/d41586-021-02854-3

Abbas-Hanif, A., Modi, N., Smith, S. K., & Majeed, A. (2021). Covid-19 treatments and vaccines must be evaluated in pregnancy. BMJ, n2377. https://doi.org/10.1136/bmj.n2377

The COVID-19 vaccine race | Gavi, the Vaccine Alliance. (n.d.). Retrieved October 8, 2021, from https://www.gavi.org/vaccineswork/covid-19-vaccine-race

Flu and Covid jabs safe to be given at same time, study finds | Vaccines and immunisation | The Guardian. (n.d.). Retrieved October 1, 2021, from https://www.theguardian.com/society/2021/sep/30/flu-covid-jabs-safe-same-time-study?CMP=Share_iOSApp_Other

Mel 💉🩹❤️Get Vaccinated! On Twitter: “#GetVaccinatedNow https://t.co/ewb1vQCvWw” / Twitter. (n.d.). Retrieved August 27, 2021, from https://twitter.com/ScientistMel/status/1430927342361137156

Kadambari, S., & Vanderslott, S. (2021). Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK. The Lancet Infectious Diseases, S1473309921004047. https://doi.org/10.1016/S1473-3099(21)00404-7

PINHO, A. C. (2021, March 10). EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesevimab for COVID-19 [Text]. European Medicines Agency. https://www.ema.europa.eu/en/news/ema-starts-rolling-review-eli-lilly-antibodies-bamlanivimab-etesevimab-covid-19

How long do COVID vaccines take to start working? (n.d.). Retrieved June 29, 2021, from https://theconversation.com/how-long-do-covid-vaccines-take-to-start-working-161876?utm_source=twitter&utm_medium=bylinetwitterbutton

Lipsitch, M., & Kahn, R. (2021). Interpreting vaccine efficacy trial results for infection and transmission. Vaccine, 39(30), 4082–4088. https://doi.org/10.1016/j.vaccine.2021.06.011

40 Iowa infectious disease doctors recommend COVID-19 vaccines. (n.d.). Retrieved June 28, 2021, from https://eu.desmoinesregister.com/story/opinion/columnists/iowa-view/2021/06/27/iowa-infectious-disease-doctors-recommend-covid-19-vaccines/7777363002/

Duarte-Salles, T., & Prieto-Alhambra, D. (2021). Heterologous vaccine regimens against COVID-19. The Lancet, S0140673621014422. https://doi.org/10.1016/S0140-6736(21)01442-2

Borobia, A. M., Carcas, A. J., Pérez-Olmeda, M., Castaño, L., Bertran, M. J., García-Pérez, J., Campins, M., Portolés, A., González-Pérez, M., García Morales, M. T., Arana-Arri, E., Aldea, M., Díez-Fuertes, F., Fuentes, I., Ascaso, A., Lora, D., Imaz-Ayo, N., Barón-Mira, L. E., Agustí, A., … Torvisco, J. M. (2021). Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet, S0140673621014203. https://doi.org/10.1016/S0140-6736(21)01420-3

Covid-19 vaccine did not kill every animal it was tested on—Full Fact. (n.d.). Retrieved June 27, 2021, from https://fullfact.org/online/covid-vaccine-animal-testing/

Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., Kuntz, J. L., Dunnigan, K., Odean, M. J., Hegmann, K. T., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., … Gaglani, M. (2021). Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers—Eight U.S. Locations, December 2020–March 2021. MMWR. Morbidity and Mortality Weekly Report, 70(13), 495–500. https://doi.org/10.15585/mmwr.mm7013e3

Covid vaccine: US trial of AstraZeneca jab confirms safety—BBC News. (n.d.). Retrieved June 26, 2021, from https://www.bbc.co.uk/news/health-56479462

Parry, H. M., Tut, G., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., Leung, S., Chiplin, E., Coombes, N. S., Bewley, K. R., Penn, E. J., Rowe, C., Otter, A., Watts, R., D’Arcangelo, S., … Moss, P. (2021). BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3816840

A Few People Developed a Rare Blood Disorder, Immune Thrombocytopenia, After Getting a COVID Vaccine | Health.com. (n.d.). Retrieved March 17, 2021, from https://www.health.com/condition/infectious-diseases/coronavirus/rare-blood-disorder-covid-vaccine-thrombocytopenia

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

Siemieniuk, R. A., Bartoszko, J. J., Ge, L., Zeraatkar, D., Izcovich, A., Kum, E., Pardo-Hernandez, H., Rochwerg, B., Lamontagne, F., Han, M. A., Liu, Q., Agarwal, A., Agoritsas, T., Chu, D. K., Couban, R., Darzi, A., Devji, T., Fang, B., Fang, C., … Brignardello-Petersen, R. (2020). Drug treatments for covid-19: Living systematic review and network meta-analysis. BMJ, 370. https://doi.org/10.1136/bmj.m2980

Califf, Robert M., Adrian F. Hernandez, and Martin Landray. ‘Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments: Observational Cacophony, Randomized Harmony’. JAMA 324, no. 7 (18 August 2020): 625–26. https://doi.org/10.1001/jama.2020.13319.

Field, S. M., Hoek, J. M., de Vries, Y. A., Linde, M., Pittelkow, M., Muradchanian, J., & van Ravenzwaaij, D. (2020, July 30). Rethinking Remdesivir for COVID-19: A Bayesian Reanalysis of Trial Findings. https://doi.org/10.31222/osf.io/2kam7

215 clinical trials

337 clinical trials